[
  {
    "ts": "2026-02-27T06:12:56+00:00",
    "headline": "OPKO Health Q4 Earnings Call Highlights",
    "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
    "url": "https://www.marketbeat.com/instant-alerts/opko-health-q4-earnings-call-highlights-2026-02-27/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "dd806182-0eae-32d0-811a-6e88e478e7cb",
      "content": {
        "id": "dd806182-0eae-32d0-811a-6e88e478e7cb",
        "contentType": "STORY",
        "title": "OPKO Health Q4 Earnings Call Highlights",
        "description": "",
        "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
        "pubDate": "2026-02-27T06:12:56Z",
        "displayTime": "2026-02-27T06:12:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/0fe17915329fe8a1b1ee875d2f740a8b",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "OPKO Health logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.YovMSQF8MmNuK.DrboSnA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/0fe17915329fe8a1b1ee875d2f740a8b.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vvujk3V5knBCFK3IoQs_rw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/0fe17915329fe8a1b1ee875d2f740a8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/opko-health-q4-earnings-call-highlights-2026-02-27/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/opko-health-q4-earnings-call-061256104.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPK"
            },
            {
              "symbol": "LH"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T15:15:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer reg",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-paclitaxel-without-151500524.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2d070d64-d2f6-3ac7-aa8e-70ae0b7285e1",
      "content": {
        "id": "2d070d64-d2f6-3ac7-aa8e-70ae0b7285e1",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
        "description": "",
        "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer reg",
        "pubDate": "2026-02-27T15:15:00Z",
        "displayTime": "2026-02-27T15:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/8eb769ba2d92c371f856ccb19f65ad94",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XRwvt6aDSGOEdbkXAhHuTQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8eb769ba2d92c371f856ccb19f65ad94.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ay._mo0VJwTbtiP7Aa.j9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8eb769ba2d92c371f856ccb19f65ad94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-paclitaxel-without-151500524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-paclitaxel-without-151500524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T15:00:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-150000014.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5ff7eea3-2a78-3952-8904-42b57f1a64a6",
      "content": {
        "id": "5ff7eea3-2a78-3952-8904-42b57f1a64a6",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
        "description": "",
        "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will",
        "pubDate": "2026-02-27T15:00:00Z",
        "displayTime": "2026-02-27T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/fa8e0006b54004d56aaaf67802e05993",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fz0C4KXs9KQBJOcYtLN4eQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fa8e0006b54004d56aaaf67802e05993.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/msrNIuWYrXl2KQrbKf6tuQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fa8e0006b54004d56aaaf67802e05993.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-150000014.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-150000014.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]